| |
Revolutionize your clinical trial! IQVIA experts discuss how the synergy between wearables and eCOA will enhance data collection, patient engagement, regulatory compliance and streamline trial processes. Watch this webinar replay now.
|
|
Today’s Big NewsJul 18, 2025 |
| By Fraiser Kansteiner Following a tumultuous week for Sarepta Therapeutics, the biotech has confirmed that a third patient has died after receiving one of the company’s gene therapies. While the previous two deaths occurred in patients treated with Elevidys, the most recent patient was receiving one of Sarepta's investigational treatments. |
|
|
|
By James Waldron The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed threat of a tariff on pharmaceuticals. |
By Darren Incorvaia As measles cases surge to record levels in the U.S., Department of Health and Human Services Secretary Robert F. Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments for the virus. |
Sponsored by Evernorth Specialty Services Choosing the right specialty pharmacy partner is critical. Especially when you’re treating rare, chronic and complex conditions. You need a partner who delivers more than just logistics management, therapy fulfillment and generalized patient care. |
|
Overcome biotherapeutic protein expression challenges with advanced vector technology for a range of multi-gene and difficult to express proteins. Watch the presentation to learn more.
|
|
By Darren Incorvaia,Zoey Becker Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a massive overhaul of its organization. The company’s chief customer officer Dallan Murray is headed out the door, to be replaced by Patrick Moss, formerly senior vice president of U.S. market access and sales and now chief commercial officer. |
By Gabrielle Masson The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens and protect against emerging public health threats. |
By Zoey Becker Members of the FDA's Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side effects, proposed dosing and a lack of diversity in GSK's trial program. |
By Kevin Dunleavy Bain Capital and Botanic Properties have broken ground on a unique biomanufacturing facility in Bedford, Mass., which is designed to house multiple companies operating separately in highly regulated manufacturing suites. The joint venture is dubbed GenesisM. |
By Ayla Ellison In this episode of "The Top Line," we explore how pharma marketing is evolving—and what early-career professionals need to know to grow and stand out in a rapidly changing, highly regulated industry. |
By Conor Hale CEO Robert Ford said sales of its Navitor TAVR implant have doubled over the past two years, and that the road ahead looks favorable. |
By Nick Paul Taylor Neurologists think more in terms of drug class and indication than in brand names, according to a ZoomRx survey with implications for how marketers communicate with physicians. |
By Angus Liu Biotech deals involving assets developed in China are surging, a Jefferies report shows. Takeda is preparing its narcolepsy candidate oveporexton for an FDA filing after two positive phase 3 readouts. Merck & Co.'s PD-1xVEGF partner is being acquired. And more. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," we explore how pharma marketing is evolving—and what early-career professionals need to know to grow and stand out in a rapidly changing, highly regulated industry. |
|
|---|
|
|
| WhitepaperThis white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
| WhitepaperPresented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| |
|
